Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

http://www.wikidata.org/entity/Q51012796

about

Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Intravenous immunoglobulin and Alzheimer's disease: what now?Tau-targeted treatment strategies in Alzheimer's disease Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells Alzheimer's disease: Unique markers for diagnosis & new treatment modalities Immunological memory to hyperphosphorylated tau in asymptomatic individuals.A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease.Immunogenic properties of amyloid beta oligomers.Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.γ-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment.IgG Conformer's Binding to Amyloidogenic Aggregates.Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.Molecular biomarkers in glaucoma Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia.Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment.Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.Pathogenic and physiological autoantibodies in the central nervous system.Immunotherapy for Alzheimer disease: the challenge of adverse effects.Plant-based vaccines for Alzheimer's disease: an overview.Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.Immunomodulation and AD--down but not out.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin.Assembly of synthetic Aβ miniamyloids on polyol templates.

P2860

Q26740418-931442F9-5A79-46BA-88BC-C41018B03CFE Q26752508-C04BCA0E-6C75-44E9-98D7-3DA6C9EC1A0A Q26822002-80A4B825-8A26-4C6A-89A3-F4558C19E111 Q27000371-63267E35-A642-407E-9EA1-EF64AC0EECA4 Q27023429-C3AF8ECB-5B54-4986-894A-E9D778F6D03A Q27317159-CA4467B8-5B55-4F51-9294-29E464595B4A Q28085139-D695722B-193E-4593-9E24-4F2EB1838A62 Q33559360-E118D1AD-D2A8-415E-8DFC-45A6E8C35F53 Q33853280-5224F743-33E1-47F4-ABBD-8C8E8D4F2257 Q34329254-714A05D1-AACF-4055-A6A4-3D0544304ACE Q34413715-E6CC2188-3D9B-43DE-BC69-40C8026685DC Q34473306-6FCA8F0B-F565-4213-82E2-C9A2733CF394 Q34500145-86518C09-EE7B-4AB4-B5D2-B3BA05625BD3 Q34518856-23676080-E87C-4DA9-B4B5-56E59312C341 Q34627859-03662494-F15A-43A7-BBC6-2690F61510F3 Q34733689-CBEC188B-D395-4770-84C1-C24D3AFDF68E Q35111136-1CF0CC0B-3642-4AF9-A27B-3E73CCE2F967 Q35184148-D3F5D446-8D37-48A5-8D82-4817CD670188 Q35541293-534E38D1-C5AB-431A-B9D8-9D35E6672EA8 Q35590968-361488E1-C96C-4D02-AE2E-E2A3C918725F Q35772596-69ADAEE5-4B29-43B7-908A-D8A69F7FC4D6 Q36156604-2DA39ED7-0CDC-4740-9C31-75FFCD5DD0F3 Q36179280-A9B0923E-5DFD-4770-8102-61CA25889555 Q36342218-3771F061-40B9-462B-BEE3-E543DD0B033E Q36530573-1327230F-AC64-4349-BC73-ED6D85278E04 Q36689356-62D1215E-B18A-47F7-A321-A701DA571CF4 Q36764469-3032CFF8-72A5-4146-B659-E3035D083A0D Q36894417-C5049350-174F-4306-B035-2CD804EB2222 Q37024947-D57DB276-71D1-4A94-9F16-3A485750E774 Q37044228-C829A0A2-A4BD-427D-B432-E639124FCD31 Q37141684-D73986DE-9087-4DAF-9856-EF8B724956B8 Q38020957-B02D6379-D438-4F06-8609-A430F919C4E9 Q38023156-2DC0036C-BF9B-48EF-BB0F-BA0D4B80487B Q38176962-72642933-C183-444C-811C-883A7AE90163 Q38204711-BA1A4A61-7C98-4E91-B712-18F614F1091A Q38208226-C1C65F78-0D01-4BC3-95A7-E3AB3E1C2B17 Q38283308-8432ECE1-A8C6-439C-8D61-2BE690AB7DAC Q39062945-EFE45088-AA1F-497A-8651-8DA7222BEBA6 Q40986104-B2463CE0-F4A7-4884-8F24-00133BD72243 Q41864632-3229B5A9-1B2E-49A9-9DC0-7450822DA314

P2860

Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.

http://www.wikidata.org/entity/Q51012796

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Naturally occurring autoantibo ...... models of Alzheimer's disease.

@en

Naturally occurring autoantibo ...... models of Alzheimer's disease.

@nl

type

label

Naturally occurring autoantibo ...... models of Alzheimer's disease.

@en

Naturally occurring autoantibo ...... models of Alzheimer's disease.

@nl

prefLabel

Naturally occurring autoantibo ...... models of Alzheimer's disease.

@en

Naturally occurring autoantibo ...... models of Alzheimer's disease.

@nl

P1433

Q51012796-D3F7BA31-12AD-481B-86BC-849844CF3491

P1476

Q51012796-E3F51A93-BCBE-4F43-BED5-2200EAC821F2

P2093

Q51012796-0D449DA0-6F4A-4805-ADB4-E3CD6B1BB80D

Q51012796-11179238-C5F2-451D-8CBB-90D973B8D1E9

Q51012796-14DBA1F2-5524-4954-84DA-240E690BA494

Q51012796-1C31B9FA-C401-409B-8ABA-E901FD548017

Q51012796-3A31EBBE-19BE-41C4-89D9-9874BC633F6D

Q51012796-6048861A-A702-47E9-896B-2370AE9CE510

Q51012796-650C4A94-CE47-4AA5-B359-47A06C727807

Q51012796-6E61CA76-0AD9-46AE-81BE-9E2F5724484F

Q51012796-6EA80145-F430-45EF-918E-BDC20D5DBA7E

Q51012796-72B4420A-A8F8-4775-9008-32FEE92C9890

P304

Q51012796-B6F3D271-3BB8-4CFD-A9EA-2B63B21C8AEC

P31

Q51012796-30235921-EB9A-4FAC-A054-23E39D70A9FD

P356

Q51012796-15AA138E-2ED2-4301-A7BC-AF73D820E29D

P407

Q51012796-DCFAD375-4B39-4A08-82FF-1E58256C2105

P433

Q51012796-A36E1237-78B1-4DB9-A371-03752F037E4A

P478

Q51012796-59BC83D7-677A-486B-A44A-8B413D2F87EC

P50

Q51012796-C94FCB38-B8BD-4CFF-8615-B5DD71D60503

P577

Q51012796-539E6DC0-2C2F-4A46-957C-8D037BE9042D

P5875

Q51012796-AC6AC2B7-FB55-4BC7-AD25-DE17668249AF

P698

Q51012796-FCF8EA73-142B-47B4-8A3C-FE84E4EE33DC

P921

Q51012796-320B8DAA-4FE4-414A-9BB6-A6A568BFC6DF

P932

Q51012796-E0A6B281-836F-4130-8D5D-9E731A825A06

P356

JNEUROSCI.4401-10.2011

P1433

Journal of Neuroscience

P1476

Naturally occurring autoantibo ...... models of Alzheimer's disease

@en

P2093

Carmen Noelker

http://www.w3.org/2001/XMLSchema#string

Carsten Stüer

http://www.w3.org/2001/XMLSchema#string

Frauke Neff

http://www.w3.org/2001/XMLSchema#string

Karthikeyan Balakrishnan

http://www.w3.org/2001/XMLSchema#string

Kathy Keyvani

http://www.w3.org/2001/XMLSchema#string

Luminita-Cornelia Andrei-Selmer

http://www.w3.org/2001/XMLSchema#string

Michael Bacher

http://www.w3.org/2001/XMLSchema#string

Monika Balzer-Geldsetzer

http://www.w3.org/2001/XMLSchema#string

Oliver Deuster

http://www.w3.org/2001/XMLSchema#string

Richard Dodel

http://www.w3.org/2001/XMLSchema#string

P304

5847-5854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.4401-10.2011

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang H. Oertel

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51048654

http://www.w3.org/2001/XMLSchema#string

P698

21490226

http://www.w3.org/2001/XMLSchema#string

P921

P932

6622820

http://www.w3.org/2001/XMLSchema#string